Pharma battle

By CHRIS ILLING CCO @ ActivTrades Corp

PHARMACEUTI-

CAL companies typically compete with each other in various areas such as research and development, marketing and sales. Some of the biggest pharmaceutical companies in the world include Pfizer, Novartis, Roche, Merck & Co and Sanofi, and all of them are being traded on the various stock exchanges.

The latest battlefield is the market for weight loss products and weight loss management, which is forecast to reach about $400bn in size by 2030. The growth of this market is attributed to the increasing rate of obesity and rise in lifestyle diseases. But pharmaceutical companies are not the only competitors in the weight loss industry. Other competitors include companies that produce weight loss supplements, fitness and wellness programs, and even surgery centers that offer bariatric surgery as a weight loss solution. There is also competition from natural remedies and lifestyle changes such as exercise and diet modifications. But a new type of drug is generating excitement among the pharmaceutical companies as well as the rich and beautiful. Hollywood stars love it. Kim Kardashian swears by it, and Elon Musk has used it successfully. Just one injection is enough, and the pounds will melt off. Sounds pretty tempting. A real hype has already broken out in social media networks. The new class of drugs is called GLP-1 recptor agoinists. It is already being sold by Novo Nordisk under the brand name Wegovy in the US, Denmark and Norway, and will soon be available in other countries. Ozempic, a lower-dose version, is a diabetes drug that is also being used ‘off label’ for weight loss. The drug is only approved for the treatment of diabetes and obesity. For these people, the syringe is obviously a game changer. Wegovy has been difficult to obtain since its approval in 2021. Due to manufacturing issues, supplies were